about
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibImmunoglobulin GM and KM Allotypes and Prevalence of Anti-LKM1 Autoantibodies in Patients with Hepatitis C Virus InfectionAnti-ganglioside antibodies in coeliac disease with neurological disordersCeliac disease in autoimmune cholestatic liver disorders.Smooth muscle antibodies and type 1 autoimmune hepatitis.Antinuclear antibodies as ancillary markers in primary biliary cirrhosis.Review article: autoimmune hepatitis -- current management and challenges.Autoimmune enteropathy and rheumatoid arthritis: a new association in the field of autoimmunity.Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitisA Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosisHepatitis C and autoreactivity.Autoimmune liver disease 2007.Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value.HCV and autoimmunity.Diagnosis and therapy of autoimmune hepatitis.Current topics in autoimmune hepatitis.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis.PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis.Sera of patients with celiac disease and neurologic disorders evoke a mitochondrial-dependent apoptosis in vitro.The evolutionary scenario of hepatocellular carcinoma in Italy: an update.Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases.Susceptibility to thyroid disorders in hepatitis C.A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis.Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound.The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome.Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C.Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study.Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.Treatment of hepatocellular carcinoma in Child-Pugh B patients.Autoimmune hepatitis in Italy: the Bologna experience.Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis.Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C.Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factorsStereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis - Authors' replyCholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging
P50
Q26765210-AEE9E56A-30C8-4BC7-83EB-884ED16AF0D3Q27473220-4A6F2419-FF24-496D-BDD8-551DDF3B123DQ28295544-92B38952-D848-41BF-BB3B-723B4FC503F1Q34154921-E2D55D79-4BD0-4A5A-BC3B-CBBF199F7AADQ34199651-FD37534F-692A-4956-8C7A-A01F8AD9FF84Q34237440-459E204A-C351-40AE-926D-FE383AEDA7BAQ34369116-A1EBE599-92B5-4C8D-AC7F-BE40CD2DC748Q34558850-C7B7A448-2AD1-4588-BDC3-ECF6045D944EQ35769853-928C7EE6-2018-42F8-B482-3F4F971065EBQ36557901-E12E9903-C69F-40EE-99EA-D04CF37B5F93Q36971046-1B168546-BB60-4D7A-BFFB-50979F942495Q37027696-D70530B1-42DE-402A-A828-7BF700F95DAAQ37154299-4F22F95B-69B1-411D-BAF9-D1648C583E43Q37232835-387A0D05-B3B7-4516-99B6-72D458D9D5C5Q37516140-B3D9BBD4-3414-4986-BA27-CA69CDC927EAQ37771112-654C540B-88CB-46E5-A819-F9BE8DB347D0Q38785510-AD51A8C6-7601-4BED-9929-BB8928F4C87CQ39142012-3AA987C0-6FA1-4465-9855-E1150A491067Q39782708-2339773A-1587-4CE5-B802-3D1B7AF87221Q40107136-E6C130BB-0EB5-4625-B970-6DACA06B02C3Q40646684-226FC05B-E227-4608-83F6-F81EF11DD263Q41090958-50534F0C-1E9C-4D6E-B227-5226477C123BQ41754691-A3607F9E-199A-4852-AAD2-11C54227809DQ41937355-0A9EEE9B-A672-4C79-8823-5FF360D5F982Q42993073-21A61D6C-F87B-416D-B38E-046DB014D62EQ44739483-0DE1324F-B77A-4062-A84D-CFF22864787AQ45809695-E5FC6D76-FEEB-4CCF-9537-F935A01FA8B7Q45985033-4AF76E74-48ED-42DE-BB40-0EAE50C6F222Q46034647-CF656D70-F49C-4AB1-934E-FE072A507412Q46476276-F612A840-6496-445C-83FE-0BD09E68B45BQ46789982-956EE348-2C70-44CB-B7DD-7D4E5BDC056DQ46966352-1C140A0E-32EB-4AAF-A18B-057AC17346A3Q47939731-43524DE8-52D6-418E-8E53-51750C0C6E64Q50579651-A550A375-4D37-474F-A6AB-7FD4CF2CA99DQ51757906-1A65BC60-F744-4FC9-B731-DD608754012CQ53111728-F2E94A19-5C75-4C97-B2ED-33677925167CQ54567921-B63483A5-58B5-419C-98E5-6E11F05CBCBBQ56369454-AD48EC38-3D94-414F-B716-69B09144BD17Q56960702-1128AA85-2EF7-488A-A679-FBC4AD3E27A0Q56968191-92D3487D-024D-4D97-B093-51402C679A6F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandro Granito
@ast
Alessandro Granito
@en
Alessandro Granito
@es
Alessandro Granito
@nl
type
label
Alessandro Granito
@ast
Alessandro Granito
@en
Alessandro Granito
@es
Alessandro Granito
@nl
prefLabel
Alessandro Granito
@ast
Alessandro Granito
@en
Alessandro Granito
@es
Alessandro Granito
@nl
P106
P1153
6601985704
P21
P31
P496
0000-0002-0637-739X